bosentan anhydrous has been researched along with monocrotaline in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (10.53) | 18.2507 |
| 2000's | 4 (21.05) | 29.6817 |
| 2010's | 11 (57.89) | 24.3611 |
| 2020's | 2 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Clozel, JP; Clozel, M; Hess, P | 1 |
| Hill, NS; Klinger, JR; Pietras, L; Warburton, RR | 1 |
| Brás-Silva, C; Correia-Pinto, J; Faria, B; Henriques-Coelho, T; Leite-Moreira, AF; Lourenço, AP; Roncon-Albuquerque, R; Wieland, J | 1 |
| Binkert, C; Clozel, M; Hess, P; Iglarz, M; Qiu, C; Rey, M | 1 |
| Baloira, A | 1 |
| He, JG; Tan, XY | 1 |
| de Boer, MA; Mouchaers, KT; Postmus, PE; Schalij, I; van der Laarse, WJ; van Hinsbergh, VW; van Nieuw Amerongen, GP; Vonk Noordegraaf, A | 1 |
| Bilan, VP; Jackson, EK; Jones, TJ; Petrusevska, G; Tofovic, SP | 1 |
| Hamidi, SA; Jiang, YP; Lin, RZ; Lyubsky, S; Said, SI; Szema, AM | 1 |
| Sirmagul, B; Yigitaslan, S | 1 |
| Ceribasi, AO; Demir, T; Dokuyucu, R; Kaplan, DS; Kisacik, B; Koc, I; Onat, AM; Orkmez, M; Pehlivan, Y; Taysi, S; Turkbeyler, IH; Tutar, E | 1 |
| Fontoura, D; Leite, S; Leite-Moreira, AF; Lourenço, AP; Mendes-Ferreira, P; Oliveira-Pinto, J; Tavares-Silva, M; Vasques-Nóvoa, F | 1 |
| Buyukakilli, B; Citirik, D; Gurgul, S; Hallioglu, O; Ozeren, M; Tasdelen, B | 1 |
| Balli, E; Buyukakilli, B; Gurgul, S; Hallioglu, O; Karpuz, D; Ozeren, M; Tasdelen, B | 1 |
| Kim, SH; Lee, GJ; Li, W; Park, BM; Yu, L | 1 |
| Kang, JH; Kim, DW; Kim, JY; Kwon, YB; Lee, HJ; Oh, DW; Park, CW; Park, ES; Rhee, YS; Shin, DH | 1 |
| Chen, D; Chen, Y; Du, G; Fang, L; Niu, Z; Yuan, T; Zhang, H | 1 |
19 other study(ies) available for bosentan anhydrous and monocrotaline
| Article | Year |
|---|---|
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Telemetry monitoring of pulmonary arterial pressure in freely moving rats.
Topics: Animals; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Bosentan; Cardiac Catheterization; Hypertension, Pulmonary; Male; Monocrotaline; Motor Activity; Organ Size; Pulmonary Artery; Rats; Rats, Wistar; Sulfonamides; Telemetry; Weight Gain | 1996 |
Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats.
Topics: Animals; Antihypertensive Agents; Bosentan; Cardiac Output; Endothelin Receptor Antagonists; Endothelin-1; Hemodynamics; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Lung; Male; Monocrotaline; Neovascularization, Pathologic; Organ Size; Poisons; Pulmonary Circulation; Rats; Rats, Sprague-Dawley; Sulfonamides | 1997 |
Myocardial dysfunction and neurohumoral activation without remodeling in left ventricle of monocrotaline-induced pulmonary hypertensive rats.
Topics: Angiotensinogen; Animals; Antihypertensive Agents; Bosentan; Cytochrome P-450 CYP11B2; Endothelin-1; Gene Expression Regulation; Heart Ventricles; Hemodynamics; Hypertension, Pulmonary; Male; Monocrotaline; Myocardial Contraction; Natriuretic Peptide, Brain; Neurotransmitter Agents; Peptides, Cyclic; Peptidyl-Dipeptidase A; Rats; Rats, Wistar; RNA, Messenger; Sulfonamides; Ventricular Function; Ventricular Remodeling | 2006 |
Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats.
Topics: Animals; Bosentan; Disease Models, Animal; Drug Therapy, Combination; Endothelin Receptor Antagonists; Hypertension, Pulmonary; Male; Monocrotaline; Phosphodiesterase Inhibitors; Piperazines; Purines; Rats; Rats, Wistar; Sildenafil Citrate; Sulfonamides; Sulfones | 2006 |
[Pulmonary hypertension treatment: future prospects].
Topics: Administration, Intranasal; Administration, Oral; Animals; Bosentan; Drug Evaluation, Preclinical; Endothelin A Receptor Antagonists; Epoprostenol; Forecasting; Humans; Hypertension, Pulmonary; Iloprost; Infusions, Intravenous; Isoxazoles; Life Expectancy; Lung Transplantation; Monocrotaline; Piperazines; Platelet-Derived Growth Factor; Purines; Randomized Controlled Trials as Topic; Rats; Sheep; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes; Vasodilator Agents | 2007 |
The remodeling of connexin in the hypertrophied right ventricular in pulmonary arterial hypertension and the effect of a dual ET receptor antagonist (bosentan).
Topics: Animals; Bosentan; Connexin 43; Disease Models, Animal; Endothelin Receptor Antagonists; Gap Junctions; Hemodynamics; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Microscopy, Confocal; Microscopy, Electron; Monocrotaline; Myocytes, Cardiac; Rats; Rats, Sprague-Dawley; Sulfonamides; Ventricular Remodeling | 2009 |
Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Oral; Animals; Antihypertensive Agents; Blood Pressure; Bosentan; Familial Primary Pulmonary Hypertension; Heart Ventricles; Hemodynamics; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Monocrotaline; Piperazines; Pulmonary Artery; Purines; Rats; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2010 |
Synergistic therapeutic effects of 2-methoxyestradiol with either sildenafil or bosentan on amelioration of monocrotaline-induced pulmonary hypertension and vascular remodeling.
Topics: 2-Methoxyestradiol; Animals; Antihypertensive Agents; Bosentan; Drug Synergism; Drug Therapy, Combination; Estradiol; Female; Hypertension, Pulmonary; Male; Monocrotaline; Muscle, Smooth, Vascular; Piperazines; Pulmonary Artery; Purines; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2010 |
VIP and endothelin receptor antagonist: an effective combination against experimental pulmonary arterial hypertension.
Topics: Animals; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Hypertension, Pulmonary; Monocrotaline; Rats; Rats, Sprague-Dawley; Receptors, Endothelin; Sulfonamides; Vasoactive Intestinal Peptide | 2011 |
Relation of bosentan, iloprost, and sildenafil with growth factor levels in monocrotaline-induced pulmonary hypertension.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Bosentan; Female; Hypertension, Pulmonary; Iloprost; Monocrotaline; Piperazines; Pulmonary Artery; Purines; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Sulfonamides; Sulfones; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A; Vasodilator Agents | 2012 |
Palosuran treatment effective as bosentan in the treatment model of pulmonary arterial hypertension.
Topics: Animals; Arterial Pressure; Bosentan; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Hemodynamics; Hypertension, Pulmonary; Lung; Male; Monocrotaline; Pulmonary Artery; Quinolines; Rats; Rats, Wistar; Sulfonamides; Urea; Urotensins | 2014 |
Myocardial and anti-inflammatory effects of chronic bosentan therapy in monocrotaline-induced pulmonary hypertension.
Topics: Animals; Bosentan; Disease Models, Animal; Endothelin Receptor Antagonists; Heart Ventricles; Hypertension, Pulmonary; Inflammation; Male; Monocrotaline; Rats; Rats, Wistar; Sulfonamides | 2014 |
Determination of the effects of pulmonary arterial hypertension and therapy on the cardiovascular system of rats by impedance cardiography.
Topics: Animals; Blood Pressure; Bosentan; Cardiography, Impedance; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Endothelin Receptor Antagonists; Heart Ventricles; Hypertension, Pulmonary; Male; Monocrotaline; Phosphodiesterase 5 Inhibitors; Piperazines; Pulmonary Artery; Purines; Rats, Wistar; Sildenafil Citrate; Sulfonamides | 2014 |
Clinical and histopathological relationship of sildenafil and bosentan treatments in rats with monocrotaline induced pulmonary hypertension.
Topics: Animals; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Hypertension, Pulmonary; Lung; Male; Monocrotaline; Phosphodiesterase 5 Inhibitors; Rats; Rats, Wistar; Sildenafil Citrate; Sulfonamides | 2017 |
Hypoxia augments NaHS-induced ANP secretion via KATP channel, HIF-1α and PPAR-γ pathway.
Topics: 2-Methoxyestradiol; Anilides; Animals; Atrial Natriuretic Factor; Bosentan; Gene Expression Regulation; Glyburide; Heart Atria; Hydrogen Sulfide; Hypertension, Pulmonary; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; KATP Channels; Male; Monocrotaline; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase Type III; Organ Culture Techniques; Oxygen; Pinacidil; Potassium Channel Blockers; PPAR gamma; Rats; Rats, Sprague-Dawley; Signal Transduction; Sulfides | 2019 |
Inhaled bosentan microparticles for the treatment of monocrotaline-induced pulmonary arterial hypertension in rats.
Topics: Administration, Inhalation; Animals; Bosentan; Dry Powder Inhalers; Monocrotaline; Particle Size; Pulmonary Arterial Hypertension; Rats | 2021 |
DL0805-1, a novel Rho-kinase inhibitor, attenuates lung injury and vasculopathy in a rat model of monocrotaline-induced pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Bosentan; Disease Models, Animal; Hypertension, Pulmonary; Indazoles; Male; Monocrotaline; Nitriles; Protein Kinase Inhibitors; Pulmonary Artery; Rats; Rats, Sprague-Dawley; rho-Associated Kinases; Vasodilator Agents | 2022 |